서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 58 of 58

Issue DateTitle / Author(s) / CitationFileAltmetrics
2005-06
Cytotoxic effects of pemetrexed in gastric cancer cells
DOI
2006-09
Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells
2007-08
Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer
link
2007-12
Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection
DOI
2008-06
Atypical endoscopic features can be associated with metastasis in rectal carcinoid tumors
DOI
2009-01
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study
link
2009-02
Pathologic complete response after palliative 3rd line chemotherapy with capecitabine alone in metastatic colorectal cancer
DOI
2009-07
Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer
view fileDOI
2009-09
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study
DOI
2009-12
Role of Surgery in the Treatment of Ovarian Metastases From Colorectal Cancer
DOI
2009-12
Resected Colorectal Liver Metastases: Does the Survival Differ According to Postoperative Chemotherapy Regimen?
DOI
2010-07
PATHOLOGIC NODAL CLASSIFICATION IS THE MOST DISCRIMINATING PROGNOSTIC FACTOR FOR DISEASE-FREE SURVIVAL IN RECTAL CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMORADIOTHERAPY AND CURATIVE RESECTION

Kim, Tae Hyun; Chang, Hee Jin; Kim, Dae Yong; Jung, Kyung Hae; Kim, Sun Young; Oh, Jae Hwan; Choi, Hyo Seong; Jeong, Seung-Yong; Lim, Seok-Byung; Park, Ji Won; Hong, Yong Sang

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS; Vol.77, no.4; 1158-1165

DOI
2010-08
Influence of Preoperative Chemoradiotherapy on the Number of Lymph Nodes Retrieved in Rectal Cancer
DOI
2010-09
TUMOR VOLUME REDUCTION RATE MEASURED BY MAGNETIC RESONANCE VOLUMETRY CORRELATED WITH PATHOLOGIC TUMOR RESPONSE OF PREOPERATIVE CHEMORADIOTHERAPY FOR RECTAL CANCER

Yeo, Seung-Gu; Kim, Dae Yong; Kim, Tae Hyun; Jung, Kyung Hae; Chang, Hee Jin; Lim, Seok-Byung; Jeong, Seung-Yong; Choi, Hyo Seong; Park, Ji Won; Hong, Yong Sang

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS; Vol.78, no.1; 164-171

DOI
2010-12
The Role of Omental Flap Transposition in Patients With Locoregional Recurrent Rectal Cancer Treated With Reirradiation
DOI
2011-01
Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01)
DOI
2011-11
Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: A multicenter phase II study
DOI
2013-01
Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation
DOI
2013-01
KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: A pooled analysis of 2 phase II trials

Kim, Sun Young; Shim, Eun Kyung; Yeo, Hyun Yang; Baek, Ji Yeon; Hong, Yong Sang; Kim, Dae Yong; Kim, Tae Won; Kim, Jee Hyun; Im, Seock-Ah; Jung, Kyung Hae; Chang, Hee Jin

International Journal of Radiation Oncology Biology Physics, Vol.85 No.1, pp.201-207

DOI
2013-02
Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation (vol 71, pg 43, 2013)
DOI
2013-05
Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02
DOI
2014-02
A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer A Prospective, Multicenter Trial of the Korean Cancer Study Group
DOI
2014-05
Daily Collection of Self-Reporting Sleep Disturbance Data via a Smartphone App in Breast Cancer Patients Receiving Chemotherapy: A Feasibility Study
DOI
2014-06
Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial
DOI
2014-08
Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trial
DOI
2014-12
HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
DOI
2014-12
Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer
view fileDOI
2015-07
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)
DOI
2016-03
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
DOI
2016-04
A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09
DOI
2016-04
Circulating plasma biomarkers for TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer
DOI
2016-05
Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer
DOI
2016-10
Prognostic value of axillary nodal ratio after neoadjuvant chemotherapy of doxorubicin/cyclophosphamide followed by docetaxel in breast cancer: A multicenter retrospective cohort study
DOI
2017-04
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
DOI
2017-05
A randomized controlled trial of physical activity, dietary habit, and distress management with the Leadership and Coaching for Health (LEACH) program for disease-free cancer survivors
view filelink
2017-11
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
DOI
2017-12
Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline
DOI
2018-07
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
DOI
2018-11
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)
DOI
2018-12
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
DOI
2019-01
Landscape of actionable genetic alterations profiled from 1,071 tumor samples in Korean cancer patients
DOI
2019-01
Randomized Open Labe Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
DOI
2019-05
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
view fileDOI
2019-06
Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors
DOI
2019-09
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients
DOI
2019-11
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11)
DOI
2019-12
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
DOI
2019-12
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): A multicentre, open-label, randomised, phase 2 trial
DOI
2020-11
Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)
DOI
2020-12
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
DOI
2021-01
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
DOI
2021-07
Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)
DOI
2021-08
Genomic Profiling of Premenopausal HR+ and HER2-Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
DOI
2022-03
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2(-) Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
DOI
2022-04
Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
DOI
2022-09
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial
DOI
2024-01
Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial
DOI
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2-breast cancer
DOI
1